By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DiagnoCure has received a Clinical Laboratory Permit from New York State regulators for its CLIA-approved and CAP-certified laboratory, the company announced today.

The permit from the New York State Department of Health allows DiagnoCure's lab in West Chester, Penn., to use the company's Previstage GCC Colorectal Staging Test on commercial samples originating in New York, which could crack open a significant market for the test, DiagnoCure said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.